NASDAQ
Aura Biosciences, Inc. (AURA)
♥ 367 Thanks from members
Aura Biosciences, Inc. (AURA) maintains a strong 'Strong Buy' consensus from Wall Street analysts with an average price target of $16.60, backed by its promising virus-like drug conjugate (VDC) platform like bel-sar, a cash position extending to Q1 2027, and high institutional ownership, despite ongoing clinical trial uncertainties and negative EPS.